Tramadol is a synthetic opioid analgesic that is frequently perceived as a mild or low-risk painkiller, but this perception is misleading. While tramadol is less potent than morphine or oxycodone, it carries genuine risks of physical dependence, withdrawal, and addiction, and its dual mechanism of action (opioid receptor activation plus serotonin-norepinephrine reuptake inhibition) introduces additional dangers including seizures and serotonin syndrome that other opioids do not share. Tramadol was reclassified as a Schedule IV controlled substance in the United States in 2014 precisely because accumulating evidence demonstrated its abuse and dependence potential.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“Tramadol presents a particular clinical challenge because many patients begin using it with genuine medical prescriptions and are told it is safer than other opioids,” says Dr. Ponlawat Pitsuwan. “At Phuket Island Rehab, we see patients who have been taking tramadol daily for years, often at escalating doses, who are genuinely surprised to learn they have developed opioid dependence. The withdrawal syndrome from tramadol is distinctive and often more complicated than withdrawal from traditional opioids because of its serotonergic effects.”
How Tramadol Works: The Dual Mechanism
Tramadol is unique among opioid analgesics because it works through two distinct pharmacological mechanisms simultaneously. First, its primary metabolite, O-desmethyltramadol (M1), binds to mu-opioid receptors in the central nervous system. This is the same receptor system activated by morphine, heroin, and fentanyl, and it is responsible for tramadol’s analgesic effect and its potential for dependence. The M1 metabolite has approximately 200 times the mu-opioid receptor affinity of the parent compound, which means tramadol’s opioid effects depend heavily on the CYP2D6 enzyme that converts tramadol to M1.
Second, tramadol itself inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) in the synaptic cleft, similar to the mechanism of antidepressants such as venlafaxine (Effexor) and duloxetine (Cymbalta). This dual-action provides additional pain relief through descending pain inhibition pathways but also introduces risks that pure opioids do not carry: serotonin syndrome and lowered seizure threshold.
The CYP2D6 genetic variability adds another layer of complexity. Approximately 5 to 10% of Caucasians and 1 to 2% of Asians are poor CYP2D6 metabolisers, meaning they convert very little tramadol to its active M1 metabolite and experience minimal analgesic benefit. Conversely, 1 to 7% of the population are ultra-rapid CYP2D6 metabolisers, producing dangerously high levels of M1 from standard doses, which increases the risk of respiratory depression and overdose.
Why Tramadol Dependence Develops
The perception of tramadol as a “mild” opioid leads many prescribers and patients to underestimate its dependence potential. When taken regularly, tramadol produces the same mu-opioid receptor neuroadaptation as any other opioid: the brain downregulates receptor density and reduces endogenous opioid production to compensate for the external supply. Tolerance develops, meaning higher doses are needed for the same pain relief. Physical dependence follows, meaning discontinuation produces withdrawal symptoms.
Additionally, the serotonergic and noradrenergic effects of tramadol create a separate dimension of dependence. The brain adjusts its serotonin and norepinephrine systems to account for the reuptake inhibition, and when tramadol is discontinued, these systems are also disrupted. This is why tramadol withdrawal includes symptoms not typically seen in traditional opioid withdrawal, such as severe anxiety, panic attacks, paranoia, hallucinations, depersonalisation, and numbness or tingling in the extremities.
Warning: Abrupt discontinuation of tramadol after prolonged use can trigger seizures, which are not a feature of typical opioid withdrawal. Tramadol should always be tapered gradually under medical supervision rather than stopped suddenly.
Tramadol vs. Other Opioids: Risk Comparison
| Risk Factor | Tramadol | Codeine | Oxycodone | Morphine |
|---|---|---|---|---|
| Mu-opioid potency (vs morphine) | 0.1x (parent) / 0.3x (M1 metabolite) | 0.1 to 0.15x | 1.5x | 1x (reference) |
| Seizure risk | Yes (dose-dependent, especially above 400mg/day) | Rare | Rare | Rare |
| Serotonin syndrome risk | Yes (significant with SSRIs, SNRIs, MAOIs) | No | No | No |
| CYP2D6 dependence | High (active metabolite M1) | High (converted to morphine) | Low | None |
| Withdrawal atypical symptoms | Anxiety, paranoia, hallucinations, seizures | Standard opioid withdrawal | Standard opioid withdrawal | Standard opioid withdrawal |
| Scheduling (US) | Schedule IV | Schedule II | Schedule II | Schedule II |
The Serotonin Syndrome Risk
Because tramadol inhibits serotonin reuptake, combining it with other serotonergic medications can trigger serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system. Serotonin syndrome presents on a spectrum from mild (tremor, diarrhoea, agitation) to severe (hyperthermia above 41.1°C, muscle rigidity, seizures, cardiovascular collapse). The Hunter Criteria are used for clinical diagnosis and require the presence of a serotonergic agent plus one of several clinical features including clonus, agitation, diaphoresis, tremor, and hyperreflexia.
The combinations most dangerous with tramadol include SSRIs (sertraline, fluoxetine, escitalopram), SNRIs (venlafaxine, duloxetine), MAOIs (phenelzine, tranylcypromine), triptans (sumatriptan), and the antibiotic linezolid. Given that many people with chronic pain also take antidepressants, the potential for serotonin syndrome with tramadol is a real and often underappreciated clinical concern. This interaction profile is unique to tramadol among opioid analgesics and is one reason it is not simply a “weaker version” of other opioids.
Tramadol Withdrawal: What to Expect
Tramadol withdrawal combines traditional opioid withdrawal symptoms with atypical symptoms related to its serotonergic and noradrenergic effects. The traditional opioid component includes muscle aches, restlessness, anxiety, insomnia, lacrimation, rhinorrhoea, sweating, nausea, diarrhoea, and opioid craving. These typically begin 12 to 24 hours after the last dose and peak at days 2 to 4.
The atypical component, sometimes called “atypical tramadol withdrawal,” includes severe anxiety or panic attacks, paranoia, confusion, depersonalisation and derealisation (feeling detached from yourself or reality), hallucinations (auditory and visual), extreme mood swings, and paraesthesias (numbness and tingling). These symptoms can be distressing and disorienting, and they do not respond to the medications typically used for standard opioid withdrawal management. The seizure risk during tramadol withdrawal is dose-dependent and is highest in patients who were taking more than 400 mg per day or who discontinue abruptly.
Clinical insight: Tramadol withdrawal management at Phuket Island Rehab involves a gradual taper rather than abrupt cessation, specifically to minimise seizure risk. The atypical psychiatric symptoms may require short-term anxiolytic support and, in some cases, low-dose antipsychotic medication for hallucinations. Patients are monitored closely for any signs of serotonin syndrome during the tapering process, particularly if they are also discontinuing concurrent serotonergic medications.
Tramadol in Countries with Weak Prescription Controls
Tramadol misuse is a particularly significant problem in regions where it is available over the counter or with minimal prescription oversight. In parts of West Africa, the Middle East, and Southeast Asia, tramadol has become a widely misused substance, often taken at doses of 400 to 2,000 mg per day for its stimulant and euphoric effects. The WHO Expert Committee on Drug Dependence reviewed tramadol multiple times and noted increasing global reports of dependence, diversion, and tramadol-related deaths. In several countries, tramadol-related seizures and deaths have prompted regulatory reclassification.
In Thailand and much of Southeast Asia, tramadol was historically more loosely regulated than in Western countries. This accessibility, combined with the perception that it is not a “real” opioid, has contributed to dependence patterns that patients may not recognise as opioid use disorder. At Phuket Island Rehab, patients presenting with tramadol dependence often have longstanding use histories and require education about the opioid nature of their dependence alongside medical withdrawal management.
When Substance Use Has Become More Than Occasional
Tramadol dependence frequently develops gradually, often beginning with a legitimate prescription for pain. The early signs include needing higher doses for the same pain relief (tolerance), taking tramadol more often or in larger amounts than prescribed, continuing to take tramadol after the original pain condition has resolved, feeling anxious or unwell when a dose is missed, and organising daily life around ensuring a supply of the medication. If you recognise these patterns, you are likely experiencing opioid dependence, regardless of tramadol’s reputation as a mild painkiller.
The DSM-5 criteria for opioid use disorder apply to tramadol just as they do to heroin or fentanyl. The presence of two or more criteria within a twelve-month period constitutes a diagnosis. Seeking help early, before tolerance has escalated to very high doses and before the atypical withdrawal complications become more pronounced, significantly improves treatment outcomes. Medical detoxification in a supervised setting like Phuket Island Rehab ensures that the taper is managed safely, the seizure risk is mitigated, and the psychological symptoms of withdrawal are properly supported.
Summary
Tramadol’s reputation as a mild painkiller obscures genuine clinical risks. Its dual mechanism of action means it carries not only the standard opioid risks of tolerance, dependence, and respiratory depression but also unique risks of seizures and serotonin syndrome that are not shared by other opioids. Dependence develops through the same neuroadaptive processes as any opioid, and withdrawal is often more complex due to the additional serotonergic and noradrenergic components. Safe discontinuation requires gradual tapering under medical supervision.
“The most important thing I can communicate about tramadol is that being lower-potency does not mean being low-risk,” says Dr. Ponlawat Pitsuwan. “We treat tramadol dependence with the same clinical seriousness as any opioid use disorder, because the brain changes are fundamentally the same. The difference is that tramadol adds complications that require specific expertise to manage safely, particularly the seizure risk during withdrawal and the potential for serotonin syndrome when patients are on concurrent psychiatric medications.”
Frequently Asked Questions
Is tramadol really an opioid?
Yes. Tramadol is a synthetic opioid that produces its primary analgesic effect through activation of mu-opioid receptors via its metabolite O-desmethyltramadol (M1). While it also has serotonergic and noradrenergic properties that distinguish it from pure opioids, the opioid component is responsible for both its pain-relieving efficacy and its potential for dependence and withdrawal. It was reclassified as a Schedule IV controlled substance in the United States in 2014.
Can you overdose on tramadol alone?
Yes. Tramadol overdose can cause respiratory depression, seizures, serotonin syndrome, and death. The seizure risk increases significantly at doses above 400 to 500 mg, and ultra-rapid CYP2D6 metabolisers are at elevated risk because they convert more tramadol to its potent M1 metabolite. Combining tramadol with alcohol, benzodiazepines, or other CNS depressants substantially increases the overdose risk. Fatal tramadol overdoses have been documented even in the absence of co-ingestants.
How long does tramadol withdrawal last?
The acute phase of tramadol withdrawal typically lasts 5 to 10 days, with symptoms peaking around days 2 to 4. The traditional opioid withdrawal symptoms (muscle aches, nausea, diarrhoea) tend to resolve within the first week, but the atypical symptoms (anxiety, paranoia, depersonalisation, mood disturbance) may persist for 2 to 4 weeks or longer. Post-acute withdrawal symptoms such as insomnia, low mood, and reduced stress tolerance can continue for several months in patients who were on high doses for extended periods.
Can you take tramadol with antidepressants?
This combination carries significant risk and should only be undertaken under close medical supervision. Tramadol’s serotonin reuptake inhibition, combined with the serotonergic effects of SSRIs, SNRIs, or other antidepressants, increases the risk of serotonin syndrome. The FDA has issued a Drug Safety Communication warning about this interaction. If the combination is clinically necessary, patients should be monitored for signs of serotonin syndrome including agitation, tremor, rapid heartbeat, dilated pupils, hyperthermia, and muscle rigidity.
Is tramadol addictive if you take it exactly as prescribed?
Physical dependence (meaning withdrawal symptoms occur upon discontinuation) can develop even when tramadol is taken exactly as prescribed, particularly with daily use exceeding a few weeks. Physical dependence is a normal physiological adaptation and is not the same as addiction. However, addiction (compulsive use despite harm, loss of control, craving) can also develop from prescribed use, especially in individuals with genetic predispositions, prior substance use history, or co-occurring mental health conditions. The risk increases with longer duration of use and higher doses.
What are the alternatives to tramadol for chronic pain?
Non-opioid alternatives for chronic pain include NSAIDs (ibuprofen, naproxen) for inflammatory pain, gabapentinoids (gabapentin, pregabalin) for neuropathic pain, duloxetine for both pain and depression, physical therapy, cognitive behavioural therapy for pain (CBT-P), transcutaneous electrical nerve stimulation (TENS), and interventional procedures such as nerve blocks and spinal cord stimulation. For patients who require opioid analgesia, the decision should involve careful risk-benefit analysis with the prescribing physician, with clear treatment goals and regular reassessment.
Sources
World Health Organization. “Tramadol: Update Review Report.” WHO Expert Committee on Drug Dependence. who.int
US Food and Drug Administration. “FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines.” fda.gov
National Institute on Drug Abuse (NIDA). “Prescription Opioids DrugFacts.” National Institutes of Health. drugabuse.gov
Tramadol · O-desmethyltramadol (M1) · CYP2D6 · Mu-opioid receptor · Serotonin reuptake inhibition · Norepinephrine reuptake inhibition · Serotonin syndrome · Hunter Criteria · Seizure threshold · Schedule IV · SSRIs · SNRIs · MAOIs · Opioid use disorder · DSM-5 · Atypical withdrawal · Phuket Island Rehab